Aller au contenu principal
Accès ouvert déclaré 2025 article

Insights Into Aldosterone Regulation Through Pharmacokinetic–Pharmacodynamic Modeling of an Aldosterone Synthase Inhibitor

1Citations signalées — pas une note de qualité
1Institutions déclarées
1Pays d’affiliation déclarés

Résumé fourni par la source

Aldosterone is a mineralocorticoid hormone essential for regulating renal function and blood pressure. Despite its clinical relevance, key aspects of aldosterone pharmacokinetics (PK) and physiological dynamics remain incompletely understood. In serial stages, we developed a semi‐mechanistic pharmacokinetic–pharmacodynamic (PK‐PD) model to characterize aldosterone dynamics under conditions of circadian production and inhibition by lorundrostat, a selective aldosterone synthase inhibitor. Lorundrostat PK from published single‐ and multiple‐dose studies in healthy subjects was modeled using a linear hybrid two‐compartment model (2CM) with food‐dependent absorption and adrenal distribution. Separate assessment of aldosterone PK yielded 2CM properties that were used in defining both the circadian production and adrenal suppression by lorundrostat. Aldosterone concentrations from 24‐hour pre‐dose phases were characterized with dual harmonic circadian functions with fasting‐induced shifts in the timing and amplitude of hormone production. Lorundrostat suppression of aldosterone production was fitted with an extended indirect response model utilizing both the circadian production and 2CM aldosterone PK. Synthesis inhibition was about 90% while IC 50 values were attained at low doses. Such inhibition induced gradual compensatory increases in plasma renin activity, with rebound effects on aldosterone expected after 7 days of dosing and later. Sensitivity analysis supported the determinants of aldosterone dynamics in the model. This model provides a systems‐level framework to disentangle physiological and pharmacological drivers of aldosterone regulation, supports trial design for aldosterone synthase inhibitors, and may inform the development of more complex models for RAAS control of renal and cardiovascular function.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Insights Into Aldosterone Regulation Through Pharmacokinetic–Pharmacodynamic Modeling of an Aldosterone Synthase Inhibitor
Date Crossref
05/11/2025
Éditeur
Wiley
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Hormonal Regulation and HypertensionIon Transport and Channel RegulationRenin-Angiotensin System Studies

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.